Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock
Key stats
- Market cap
- $82.43M
- Price / Earnings ratio
- -0.7x
- EPS (TTM)
- -$6.11
- Volume
- Loading
- 52-week high
- $12.88
- 52-week low
- $2.81
Source: third-party data provider, as of November 13, 2026
Compare with CRBP
Recent news
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
CRBP
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
CRBP
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
CRBP
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
CRBPTechnical indicators
- RSI 14
- 41.26
- MACD 12/26/9
- -0.64
- EMA 9 of MACD
- -0.77
- MACD histogram
- 0.13
- SMA 50
- $5.99
- Price below SMA 50
- EMA 50
- $5.61
- Price below EMA 50
- SMA 200
- $8.41
- Price below SMA 200
- EMA 200
- $7.88
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.46 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
CRBPCorbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
CRBPCorbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
CRBPCorbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
CRBP
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
CRBP
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
CRBP
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
CRBP
3 Unconventional Cannabis Stocks to Watch in 2025
3 Unconventional Cannabis Stocks to Watch in 2025
CRBP
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
CRBP
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
CRBPAbout Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Yuval Cohen Ph.D. | CEO & Director | 1975 |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer | 1958 |
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer | 1973 |
| Mr. G. Scott Goeken J.D., M.S. | General Counsel & Corporate Secretary | — |
| Ms. Christina Bertsch M.A. | Vice President of Human Resources | — |
| Mr. Nishant C. Saxena | Chief Business Officer | — |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer | 1978 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.26
- MACD 12/26/9
- -0.64
- EMA 9 of MACD
- -0.77
- MACD histogram
- 0.13
- SMA 50
- $5.99
- Price below SMA 50
- EMA 50
- $5.61
- Price below EMA 50
- SMA 200
- $8.41
- Price below SMA 200
- EMA 200
- $7.88
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $27.00
- Average
- $31.67
- High
- $35.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -22.2 | -23.1 | ||||||||||
| 2022 | -33.9 | -26.5 | +66.1 | -36.5 | -10.2 | -15.9 | -1.9 | -20.3 | -14.7 | -22.6 | +46.4 | -26.9 |
| 2023 | +31.4 | -39.2 | +159.6 | +37.2 | +11.7 | -19.9 | -8.4 | +0.8 | +1.4 | -15.4 | +32.5 | -7.1 |
| 2024 | +318.5 | +11.2 | +12.1 | -2.5 | +14.9 | -3.4 | +19.2 | |||||
| 2025 | -21.7 | |||||||||||
| 2026 | -31.3 | +21.0 | -1.1 | +22.3 | -39.5 | -33.4 | +2.0 |
